The new facility, which is estimated to cost nearly €40 million, will be used, among other things, to expand production to serve new markets such as China. In the two - story building, which will be constructed on the current Allergopharma premises, products for the diagnosis and treatment of type 1 allergies.
Roche and Prothena Corporation have entered into a worldwide collaboration to develop and...
The European Commission has fined pharmaceuticals giants Johnson & Johnson and Novartis a...
Genmab A/S announced today it had reached an in vivo pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a [Eur]1.5 million payment (approximately DKK 11 million).
AstraZeneca today announced that the European Commission (EC) has granted Marketing Authorization to FluenzTM Tetra. Fluenz Tetra is a nasally administered four-strain live attenuated influenza vaccine for the prevention of influenza in children and adolescents from 24 months up to 18 years of age
Moberg Pharma AB has signed a deal to acquire three well established Over-The-Counter brands in the U.S. from Bayer HealthCare, LLC. Total annual sales for the brands are approximately 20 MSEK (ca 3 m$). The purchase price is 32 MSEK (4.8 m$) and is financed by available cash resources.
Alvotech today announced plans to invest $250 million in the development and manufacturing of a portfolio of biosimilar monoclonal antibodies. Alvotech’s current biosimilar assets include follow-on versions of leading monoclonal antibodies molecules, which will be brought to market by 2018.
Germany's Merck KGaA has announced plans to buy AZ Electronic Materials, which supplies high-tech materials for the electronics industry, for about 1.6 billion pounds ($2.6 billion). Pharmaceutical and high-tech materials company Merck said Thursday that it will offer 403.5 pence ($6.61) in cash.
Our annual reader survey looks at issues facing innovator companies and the CMO/CSOs that support them.
Who are the technical innovators in the US? The image we often have is that of the young Silicon Valley geek or the surfing California biopharma scientist -- sometimes brash and unafraid to challenge authority and champion new and better ideas.
A French contraceptive maker says it will begin warning women that its morning-after pill is ineffective when taken by women who weigh more than 80 kilograms (176 pounds).
Norway-based cancer drug maker Algeta ASA says it has received a preliminary takeover offer from Germany's Bayer AG that values the company at about $2.4 billion. Algeta said in a statement Tuesday that the offer is for 336 kroner ($55.11) per share; the company has nearly 44 million shares.
Swiss voters soundly rejected on Sunday a proposal to limit the pay of companies' highest-paid managers to 12 times that of their lowest-paid workers. Switzerland is home to global business players such as pharmaceutical companies Novartis and Roche; insurance groups Zurich and Swiss Re; and banks UBS and Credit Suisse.
Biopharm GmbH, Heidelberg, announced today that they have signed an agreement with Merck to cooperate with Merck Serono, the biopharmaceutical division of Merck in their research activities directed toward the molecular engineering of a biologic compound for the treatment of osteoarthritis.
The proposed legislation is part of a set of new proposals, outlined Tuesday, that are meant to address problems revealed by a series of catastrophic failures at the Stafford Hospital in central England, when hundreds of patients died unnecessarily from 2005 to 2009.
A Spanish court has ordered a German pharmaceutical company to pay compensation to 22 Spaniards born with disabilities after their mothers used the drug thalidomide during pregnancy decades ago.
The European Medicines Agency says it has finished an investigation of the way pharmaceutical giant Roche reported side effects for 19 drugs in the U.S. and has found no new safety concerns.
Elan says its shareholders have approved the sale of the company to Perrigo Co. for $8.6 billion. The company said 99.5 percent of the shares voted at a special meeting were voted in favor of the sale. That made up 66 percent of its total shares. Perrigo reached a deal to buy Elan Corp. PLC in a cash and stock deal in July.
AstraZeneca today announced plans to invest $190 million in a new facility at its global manufacturing site in Macclesfield, UK, to continue production of Zoladex, an injectable treatment for patients with prostate cancer.
Novartis says it is selling part of its diagnostics business to the Spanish health care company Grifols for $1.68 billion. Novartis says the unit it acquired in 2006 as part of Chiron, an Emeryville, California-based biotech company, had sales of $565 million in 2012.
Rickets results from a severe deficiency of vitamin D, which helps the body absorb calcium. Rickets was historically considered to be a disease of poverty among children who toiled in factories during the Industrial Revolution, and some experts have hypothesized it afflicted literary characters like Tiny Tim in Charles Dickens' "A Christmas Carol."
Drug and materials company Bayer AG says net profit rose 42 percent as sales increased for its new drugs aimed at preventing blood clots and treating the eye disease macular degeneration, while one-time expenses dropped. Net profit reached $1.01 billion.
Amarin Corp. plunged in premarket trading today after an FDA decision cast more doubt on the future of the specialty drugmaker's lead product. The company said Tuesday after markets closed that the FDA no longer considers a change in triglyceride levels enough to establish the effectiveness of a drug that aims to reduce the risk of cardiovascular problems like heart attacks in certain patients.
Novo Nordisk is recalling 3 million insulin products used for diabetes treatment in 13 European countries due to a production problem that can affect the strength of the drug. The Danish drug maker says Friday's recall affects certain batches of the prefilled insulin pen NovoMix30 FlexPen.
U.S. pharmaceutical distributor McKesson Corp. has launched an $8.3 billion takeover offer for German competitor Celesio AG. McKesson signed an agreement Thursday with German company Haniel to acquire its 50.01 stake in Celesio and is making an offer to other shareholders at 23 euros a share.
Novartis AG raised its full-year sales outlook because of delays in generic competition to its blockbuster blood pressure drug Diovan even though it said negative currency trends contributed to a 6 percent drop in its third-quarter net profit.
Evotec AG has signed an agreement with AstraZeneca in the field of kidney diseases. Initial focus of the alliance will be exploring compounds and targets with novel mechanisms that have disease-modifying potential for the treatment of chronic kidney disease.
Roche today announced plans to invest 800 million Swiss francs within its global manufacturing network to increase production capabilities for its biologic medicines over the next five years. The investment will be spread across sites in Penzberg (Germany), Basel (Switzerland), as well as Vacaville and Oceanside (USA).
- Page 1